SwePub
Sök i SwePub databas

  Utökad sökning

AND är defaultoperator och kan utelämnas

Träfflista för sökning "AMNE:(MEDICAL AND HEALTH SCIENCES Basic Medicine Pharmaceutical Sciences) "

Sökning: AMNE:(MEDICAL AND HEALTH SCIENCES Basic Medicine Pharmaceutical Sciences)

  • Resultat 11-20 av 4141
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
11.
  • Mohammadi, Elyas, et al. (författare)
  • Applications of Genome-Wide Screening and Systems Biology Approaches in Drug Repositioning
  • 2020
  • Ingår i: Cancers. - : MDPI AG. - 2072-6694. ; 12:9, s. 1-24
  • Forskningsöversikt (refereegranskat)abstract
    • Simple Summary Drug repurposing is an accelerated route for drug development and a promising approach for finding medications for orphan and common diseases. Here, we compiled databases that comprise both computationally- or experimentally-derived data, and categorized them based on quiddity and origin of data, further focusing on those that present high throughput omic data or drug screens. These databases were then contextualized with genome-wide screening methods such as CRISPR/Cas9 and RNA interference, as well as state of art systems biology approaches that enable systematic characterizations of multi-omic data to find new indications for approved drugs or those that reached the latest phases of clinical trials. Modern drug discovery through de novo drug discovery entails high financial costs, low success rates, and lengthy trial periods. Drug repositioning presents a suitable approach for overcoming these issues by re-evaluating biological targets and modes of action of approved drugs. Coupling high-throughput technologies with genome-wide essentiality screens, network analysis, genome-scale metabolic modeling, and machine learning techniques enables the proposal of new drug-target signatures and uncovers unanticipated modes of action for available drugs. Here, we discuss the current issues associated with drug repositioning in light of curated high-throughput multi-omic databases, genome-wide screening technologies, and their application in systems biology/medicine approaches.
  •  
12.
  • Molinaro, Angela, et al. (författare)
  • Insulin-Driven PI3K-AKT Signaling in the Hepatocyte Is Mediated by Redundant PI3Kα and PI3Kβ Activities and Is Promoted by RAS.
  • 2019
  • Ingår i: Cell Metabolism. - : Elsevier BV. - 1550-4131 .- 1932-7420. ; 29:6
  • Tidskriftsartikel (refereegranskat)abstract
    • Phosphatidylinositol-3-kinase (PI3K) activity is aberrant in tumors, and PI3K inhibitors are investigated as cancer therapeutics. PI3K signaling mediates insulin action in metabolism, but the role of PI3K isoforms in insulin signaling remains unresolved. Defining the role of PI3K isoforms in insulin signaling is necessary for a mechanistic understanding of insulin action and to develop PI3K inhibitors with optimal therapeutic index. We show that insulin-driven PI3K-AKT signaling depends on redundant PI3Kα and PI3Kβ activities, whereas PI3Kδ and PI3Kγ are largely dispensable. We have also found that RAS activity promotes AKT phosphorylation in insulin-stimulated hepatocytes and that promotion of insulin-driven AKT phosphorylation by RAS depends on PI3Kα. These findings reveal the detailed mechanism by which insulin activates AKT, providing an improved mechanistic understanding of insulin signaling. This improved model for insulin signaling predicts that isoform-selective PI3K inhibitors discriminating between PI3Kα and PI3Kβ should bedosed below their hyperglycemic threshold to achieve isoform selectivity.
  •  
13.
  • Lesén, Eva, 1982, et al. (författare)
  • Is the level of patient co-payment for medicines associated with refill adherence in Sweden?
  • 2014
  • Ingår i: European Journal of Public Health. - : Oxford University Press (OUP). - 1101-1262 .- 1464-360X. ; 24:1, s. 85-90
  • Tidskriftsartikel (refereegranskat)abstract
    • In the Swedish reimbursement scheme, the co-payment is based on the price of the product and decreases in a stepwise manner as the total accumulated co-payment increases. The aim of this study was to analyse how refill adherence in Sweden varies according to patient's co-payment level for medicines, with antiepileptic drug (AED) use as an example.
  •  
14.
  • Insulander Björk, Klara, 1982, et al. (författare)
  • Experimental determination of concentration factors of Mn, Zn and I in the phytoplankton species Phaeodactylum Tricornutum
  • 2023
  • Ingår i: Journal of Environmental Radioactivity. - : Elsevier BV. - 0265-931X .- 1879-1700. ; 261
  • Tidskriftsartikel (refereegranskat)abstract
    • Anthropogenic radionuclides released into the environment cause a radiation dose to wildlife and humans which must be quantified, both to assess the effect of normal releases, and to predict the consequences of a larger, unplanned release. To estimate the spread of the radioactive elements, the ecosystem around release points is modelled, and element uptake is usually quantified by concentration factors (CF), which relates the concentration of an element in an organism to the concentration of the same element in a medium under equilibrium conditions. In this work, we experimentally determine some phytoplankton CF that are needed for improved modelling of the marine ecosystems around nuclear facilities and release points. CFs that require better determination have been identified through literature search. Sensitivity studies, using the currently used ecosystem modelling software PREDO, show that for most studied groups, the dose committed by the respective radionuclides is almost proportional to the corresponding phytoplankton CFs. In the present work, CFs are determined through laboratory experiments with cultured phytoplankton and radionuclides of the concerned elements, assessing the element uptake by the phytoplankton through detection of the emitted radiation. The three CF assessed in this work were those for manganese, zinc and iodine in phytoplankton. Conservative estimates of these CF based on the present data are 40 000 L/kg for manganese, 50 000 L/kg for zinc and 180 L/kg for iodine with the phytoplankton masses referring to their dry weight.
  •  
15.
  • Zeybel, M., et al. (författare)
  • Multiomics Analysis Reveals the Impact of Microbiota on Host Metabolism in Hepatic Steatosis
  • 2022
  • Ingår i: Advanced Science. - : Wiley. - 2198-3844. ; 9:11, s. 2104373-
  • Tidskriftsartikel (refereegranskat)abstract
    • Metabolic dysfunction-associated fatty liver disease (MAFLD) is a complex disease involving alterations in multiple biological processes regulated by the interactions between obesity, genetic background, and environmental factors including the microbiome. To decipher hepatic steatosis (HS) pathogenesis by excluding critical confounding factors including genetic variants and diabetes, 56 heterogenous MAFLD patients are characterized by generating multiomics data including oral and gut metagenomics as well as plasma metabolomics and inflammatory proteomics data. The dysbiosis in the oral and gut microbiome is explored and the host–microbiome interactions based on global metabolic and inflammatory processes are revealed. These multiomics data are integrated using the biological network and HS's key features are identified using multiomics data. HS is finally predicted using these key features and findings are validated in a follow-up cohort, where 22 subjects with varying degree of HS are characterized.
  •  
16.
  • Altay, Özlem, et al. (författare)
  • Current Status of COVID-19 Therapies and Drug Repositioning Applications
  • 2020
  • Ingår i: Iscience. - : Elsevier BV. - 2589-0042. ; 23:7
  • Tidskriftsartikel (refereegranskat)abstract
    • The rapid and global spread of a new human coronavirus (SARS-CoV-2) has produced an immediate urgency to discover promising targets for the treatment of COVID-19. Drug repositioning is an attractive approach that can facilitate the drug discovery process by repurposing existing pharmaceuticals to treat illnesses other than their primary indications. Here, we review current information concerning the global health issue of COVID-19 including promising approved drugs and ongoing clinical trials for prospective treatment options. In addition, we describe computational approaches to be used in drug repurposing and highlight examples of in silico studies of drug development efforts against SARS-CoV-2.
  •  
17.
  • Ludvigsson, Jonas F., et al. (författare)
  • A population-based study of coeliac disease, neurodegenerative and neuroinflammatory diseases
  • 2007
  • Ingår i: Alimentary Pharmacology and Therapeutics. - : Wiley. - 0269-2813 .- 1365-2036. ; 25:11, s. 1317-1327
  • Tidskriftsartikel (refereegranskat)abstract
    • BackgroundIt has been suggested that coeliac disease (CD) is associated with several neurological diseases. However, the evidence of such an association is inconclusive as earlier research has often been based on small numbers with retrospective data collection.AimTo use Cox regression to examine the risk of neurological disease in individuals with CD.MethodsThrough Swedish national registers we identified some 14 000 individuals with a diagnosis of CD (1964–2003) and 70 000 reference individuals matched for age, sex, calendar year and county.ResultsCoeliac disease was associated with later polyneuropathy [hazard ratio (HR) = 3.4; 95% CI = 2.3–5.1]. We found no statistically significant association between CD and subsequent multiple sclerosis (HR = 0.9; 95% CI = 0.3–2.3), Parkinson’s disease (HR = 1.2; 95% CI = 0.8–1.9), Alzheimer’s disease (HR = 1.5; 95% CI = 0.9–2.6), hereditary ataxia (HR = 1.3; 95% CI = 0.5–3.6), the symptom ataxia (HR = 1.9; 95% CI = 0.6–6.2), Huntington’s disease (HR = 1.7; 95% CI = 0.3–8.6), myasthenia gravis (HR = 0.8; 95% CI = 0.2–3.8) or spinal muscular atrophy (HR = 0.5; 95% CI = 0.1–3.8). Prior polyneuropathy was associated with subsequent CD (odds ratio = 5.4; 95% CI = 3.6–8.2).ConclusionsThe association between CD and polyneuropathy indicates shared risks. We suggest that individuals with polyneuropathy routinely undergo screening for CD. There is no notable association between CD and other neurological outcomes investigated in this study.
  •  
18.
  • Saulo, Eleonor C., et al. (författare)
  • Willingness and ability to pay for artemisinin-based combination therapy in rural Tanzania
  • 2008
  • Ingår i: Malaria Journal. - London : BioMed Central. - 1475-2875. ; 7, s. 227-
  • Tidskriftsartikel (refereegranskat)abstract
    • The aim of this study was to analyse willingness to pay (WTP) and ability to pay (ATP) for ACT for children below five years of age in a rural setting in Tanzania before the introduction of artemisinin-based combination therapy (ACT) as first-line treatment for uncomplicated malaria. Socio-economic factors associated with WTP and expectations on anti-malaria drugs, including ACT, were also explored.MethodsStructured interviews and focus group discussions were held with mothers, household heads, health-care workers and village leaders in Ishozi, Gera and Ishunju wards in north-west Tanzania in 2004. Contingent valuation method (CVM) was used with "take-it-or-leave-it" as the eliciting method, expressed as WTP for a full course of ACT for a child and households' opportunity cost of ACT was used to assess ATP. The study included descriptive analyses with multivariate adjustment for potential confounding factors.ResultsAmong 265 mothers and household heads, 244 (92%, CI = 88%–95%) were willing to pay Tanzanian Shillings (TSh) 500 (US$ 0.46) for a child's dose of ACT, but only 55% (49%–61%) were willing to pay more than TSh 500. Mothers were more often willing to pay than male household heads (adjusted odds ratio = 2.1, CI = 1.2–3.6). Socio-economic status had no significant effect on WTP. The median annual non-subsidized ACT cost for clinical malaria episodes in an average household was calculated as US$ 6.0, which would represent 0.9% of the average total consumption expenditures as estimated from official data in 2001. The cost of non-subsidized ACT represented 7.0% of reported total annual expenditure on food and 33.0% of total annual expenditure on health care."Rapid effect," "no adverse effect" and "inexpensive" were the most desired features of an anti-malarial drug.ConclusionWTP for ACT in this study was less than its real cost and a subsidy is, therefore, needed to enable its equitable affordability. The decision taken in Tanzania to subsidize Coartem® fully at governmental health care facilities and at a consumer price of TSh 300–500 (US$ 0.28–0.46) at special designated shops through the programme of Accredited Drug Dispensing Outlets (ADDOs) appears to be well founded.
  •  
19.
  • Hedna, Khedidja, 1978, et al. (författare)
  • Clinical relevance of alerts from a decision support system, PHARAO, for drug safety assessment in the older adults
  • 2019
  • Ingår i: BMC Geriatrics. - : Springer Science and Business Media LLC. - 1471-2318. ; 19:1, s. 164-
  • Tidskriftsartikel (refereegranskat)abstract
    • BackgroundPHARAO is a decision support system developed to evaluate the risk for a set of either common or serious side-effects resulting from a combination of pharmacodynamic effects from a patient's medications. The objective of this study was to investigate the validity of the risk scores for the common side-effects generated by PHARAO in older patients.MethodsSide-effects included were sedation, constipation, orthostatic symptoms, anticholinergic and serotonergic effects. The alerts generated by PHARAO were tested in 745 persons 65years old. Dispensed prescriptions retrieved from the Swedish prescribed drug register were used to generate the pharmacological risk scores of patients' medications. Symptoms possibly related to side-effects were extracted from medical records data.ResultsThe PHARAO system generated 776 alerts, most often for the risk of anticholinergic symptoms. The total specificity estimates of the PHARAO system were 0.95, 0.89 and 0.78 for high, intermediate and low risk alerts, respectively. The corresponding sensitivity estimates were between 0.12 and 0.37. The negative predictive value was 0.90 and the positive predictive value ranged between 0.20-0.25.ConclusionsThe PHARAO system had a high specificity and negative predictive value to detect symptoms possibly associated with the of patients' medications, while the sensitivity and positive predictive value were low. The PHARAO system has the potential to minimise the risk of over-alerts in combination with a drug-drug interaction alert system, but should be used in connection with a medical evaluation of the patient.
  •  
20.
  • Villén, Johanna, et al. (författare)
  • Estimating environmental exposure to analgesic drugs : A cross-sectional study of drug utilization patterns in the area surrounding Sweden's largest drinking water source
  • 2023
  • Ingår i: Environmental Advances. - : Elsevier. - 2666-7657. ; 12
  • Tidskriftsartikel (refereegranskat)abstract
    • Use of pharmaceuticals is continuously increasing globally and their residues are recognized as a risk for theenvironment. The aim of this study was to investigate drug utilization patterns of analgesics in relation toenvironmental hazard in the region surrounding Sweden’s largest drinking water source, Lake Mälaren. This wasexamined using sales data on pharmaceuticals from the Swedish E-health Agency. The total sales of analgesics(non-steroidal anti-inflammatory drugs, paracetamol, other non-opioid analgesics, and opioids) for both humanand veterinary use in the region were analyzed for the years 2016 to 2020, in relation to the inherent environmental hazard for each active pharmaceutical ingredient (API). We found that a total of 454 tons of analgesicswere sold in the region during these 5 years. Classifications of environmental hazard were available for 16 out ofthe 45 studied APIs, accounting for 98.8% of the total mass in kilograms. Paracetamol, ibuprofen, and acetylsalicylic acid, which are all classified as low-hazard compounds, were the most commonly sold APIs. Diclofenac, the only pharmaceutical classified as high-hazard, was the fifth most commonly sold API, with a total soldmass of 2321 kg. The majority of the total sold mass of analgesics originated from dispensed prescriptions forhuman use in urban areas. Visualization of drug sales for humans and animals in different settings can be used toidentify the environmental burden of pharmaceuticals. Based on our study, we suggest that additional measuresto reduce the impacts of pharmaceuticals on the environment should primarily be directed to prescribing physicians in urban areas and campaigns targeted at the high over-the-counter sales of diclofenac. Moreover, it isimportant to address the fact that many pharmaceuticals currently have limited data on environmental hazard. 
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 11-20 av 4141
Typ av publikation
tidskriftsartikel (2946)
doktorsavhandling (683)
forskningsöversikt (234)
annan publikation (124)
bokkapitel (60)
konferensbidrag (57)
visa fler...
licentiatavhandling (11)
rapport (9)
bok (6)
samlingsverk (redaktörskap) (4)
patent (4)
proceedings (redaktörskap) (2)
recension (1)
visa färre...
Typ av innehåll
refereegranskat (3105)
övrigt vetenskapligt/konstnärligt (1025)
populärvet., debatt m.m. (10)
Författare/redaktör
Karlsson, Mats O. (181)
Lennernäs, Hans (126)
Artursson, Per (102)
Hammarlund-Udenaes, ... (85)
Friberg, Lena E (70)
Malmsten, Martin (67)
visa fler...
Bohlin, Lars (65)
Hallberg, Anders (58)
Nyberg, Fred (55)
Karlsson, Mats (54)
Bergström, Christel, ... (53)
Nylander, Ingrid (49)
Frenning, Göran (48)
Ashton, Michael, 195 ... (48)
Larhed, Mats (46)
Sjögren, Erik, 1977- (45)
Alderborn, Göran (45)
Hedeland, Mikael (44)
Karlén, Anders (43)
Abrahamsson, Bertil (38)
Andrén, Per E. (38)
Hallberg, Mathias (37)
Friberg, Lena (37)
Hooker, Andrew C. (36)
Wikberg, Jarl E. S. (36)
Simonsson, Ulrika S. ... (35)
Göransson, Ulf (34)
Larsson, Anette, 196 ... (34)
Samuelsson, Bertil (34)
Dorlo, Thomas P C (33)
Hansson, Per (32)
Svensson, Elin, 1985 ... (32)
Simonsson, Ulrika S. ... (32)
Schmidtchen, Artur (31)
Pettersson, Curt (31)
Bondesson, Ulf (31)
Roman, Erika (31)
Gabrielsson, Johan (30)
Bergström, Christel ... (28)
Dahlgren, David (28)
Norlin, Maria (27)
Nielsen, Jens B, 196 ... (26)
Bergström, Christel ... (26)
Wikvall, Kjell (26)
Schiöth, Helgi B. (25)
Björkman, Sven (25)
Fridén, Markus (25)
Eriksson, Tommy (24)
Backlund, Anders (24)
Kälvemark Sporrong, ... (24)
visa färre...
Lärosäte
Uppsala universitet (2990)
Göteborgs universitet (387)
Lunds universitet (338)
Karolinska Institutet (311)
Chalmers tekniska högskola (256)
Linköpings universitet (171)
visa fler...
Kungliga Tekniska Högskolan (129)
Umeå universitet (99)
Stockholms universitet (84)
Sveriges Lantbruksuniversitet (66)
Örebro universitet (47)
Linnéuniversitetet (43)
RISE (42)
Malmö universitet (32)
Luleå tekniska universitet (29)
Högskolan i Halmstad (22)
Högskolan i Borås (11)
Högskolan i Skövde (9)
Högskolan Dalarna (9)
Mittuniversitetet (5)
Högskolan i Gävle (4)
Södertörns högskola (4)
Jönköping University (3)
Karlstads universitet (3)
Mälardalens universitet (2)
Gymnastik- och idrottshögskolan (2)
Högskolan Väst (1)
Handelshögskolan i Stockholm (1)
Marie Cederschiöld högskola (1)
visa färre...
Språk
Engelska (4113)
Svenska (22)
Spanska (2)
Danska (1)
Nederländska (1)
Kinesiska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (4141)
Naturvetenskap (541)
Teknik (106)
Samhällsvetenskap (31)
Lantbruksvetenskap (28)
Humaniora (10)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy